Liquidia Technologies, Inc. Company Review & Valuation LQDA

About Liquidia Technologies, Inc.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

  • Biotechnology
  • Morrisville, North Carolina
Primary Stock Exchange Listings

Ticker Symbol:

LQDA

Nasdaq
United States

Stock Price

Performance

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Health Check

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Financial Reports

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Similar Companies

↑ back to top